Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
0.3483
-0.0047 (-1.33%)
At close: Mar 31, 2026, 4:00 PM EDT
0.3603
+0.0120 (3.45%)
After-hours: Mar 31, 2026, 7:53 PM EDT
Nexalin Technology Employees
Nexalin Technology had 6 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$50,275
Profits / Employee
-$1,370,364
Market Cap
7.17M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 6 | 0 | - | 6 | 0 |
| Dec 31, 2023 | 6 | 0 | - | 6 | 0 |
| Dec 31, 2022 | 6 | -4 | -40.00% | 6 | 0 |
| Jun 30, 2022 | 3 | 1 | 50.00% | 3 | 0 |
| Mar 31, 2022 | 10 | 6 | 150.00% | 2 | 8 |
| Dec 31, 2021 | 10 | 6 | 150.00% | 2 | 8 |
| Sep 30, 2021 | 2 | -2 | -50.00% | 2 | 0 |
| Dec 31, 2020 | 4 | - | - | 4 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Trinity Biotech | 401 |
| Vivos Therapeutics | 262 |
| Lifeward | 81 |
| Beyond Air | 61 |
| Intelligent Bio Solutions | 55 |
| Biomerica | 54 |
| enVVeno Medical | 37 |
| Tenon Medical | 27 |
NXL News
- 5 weeks ago - Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market - GlobeNewsWire
- 5 weeks ago - Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders - GlobeNewsWire
- 7 weeks ago - Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care - GlobeNewsWire
- 2 months ago - Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation - GlobeNewsWire
- 2 months ago - Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD - GlobeNewsWire
- 4 months ago - Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program - GlobeNewsWire
- 4 months ago - Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4 - GlobeNewsWire
- 4 months ago - Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity - GlobeNewsWire